These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 9401498)

  • 21. Evaluation of erythroid marrow response to recombinant human erythropoietin in patients with cancer anaemia.
    Ponchio L; Beguin Y; Farina G; Pedrazzoli P; Pedrotti C; Poggi G; Rosti V; Bergamaschi G; Battistel V; Cazzola M
    Haematologica; 1992; 77(6):494-501. PubMed ID: 1289186
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Recombinant human erythropoietin β: the effect of weekly dosing on anemia, quality of life, and long-term outcomes in pediatric cancer patients.
    Durmaz O; Demirkaya M; Sevinir B
    Pediatr Hematol Oncol; 2011 Sep; 28(6):461-8. PubMed ID: 21707225
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recombinant human erythropoietin for the treatment of chronic anemia in multiple myeloma and squamous cell carcinoma.
    Ludwig H; Pecherstorfer M; Leitgeb C; Fritz E
    Stem Cells; 1993 Sep; 11(5):348-55. PubMed ID: 8241947
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Erythropoietin treatment under polychemotherapy in patients with gynecologic malignancies: a prospective, randomized, double-blind placebo-controlled multicenter study.
    Kurz Ch; Marth Ch; Windbichler G; Lahousen M; Medl M; Vavra N; Sevelda P
    Gynecol Oncol; 1997 Jun; 65(3):461-6. PubMed ID: 9190976
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Every-2-week darbepoetin alfa is comparable to rHuEPO in treating chemotherapy-induced anemia. Results of a combined analysis.
    Mirtsching B; Charu V; Vadhan-Raj S; Colowick AB; Rossi G; Tomita D; McGuire WP
    Oncology (Williston Park); 2002 Oct; 16(10 Suppl 11):31-6. PubMed ID: 12435171
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Erythropoietin deficiency and relative resistance cause anaemia in post-renal transplant recipients with normal renal function.
    Nampoory MR; Johny KV; al-Hilali N; Seshadri MS; Kanagasabhapathy AS
    Nephrol Dial Transplant; 1996 Jan; 11(1):177-81. PubMed ID: 8649630
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Recombinant human erythropoietin treatment of anemia in renal transplant patients.
    Lezaic V; Djukanovic L; Pavlovic-Kentera V
    Ren Fail; 1995 Nov; 17(6):705-14. PubMed ID: 8771243
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Darbepoetin alfa administered every other week maintains hemoglobin levels over 52 weeks in patients with chronic kidney disease converting from once-weekly recombinant human erythropoietin: results from simplify the treatment of anemia with Aranesp (STAAR).
    Hertel J; Locay H; Scarlata D; Jackson L; Prathikanti R; Audhya P
    Am J Nephrol; 2006; 26(2):149-56. PubMed ID: 16636531
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anemia associated with advanced prostatic adenocarcinoma: effects of recombinant human erythropoietin.
    Beshara S; Letocha H; Linde T; Wikström B; Sandhagen B; Nilsson S; Danielson BG
    Prostate; 1997 May; 31(3):153-60. PubMed ID: 9167766
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prediction of response to recombinant human erythropoietin (rHuEpo) in anemia of malignancy.
    Cazzola M; Ponchio L; Pedrotti C; Farina G; Cerani P; Lucotti C; Novella A; Rovati A; Bergamaschi G; Beguin Y
    Haematologica; 1996; 81(5):434-41. PubMed ID: 8952157
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Recombinant human erythropoietin treatment in cisplatin-associated anemia: a randomized, double-blind trial with placebo.
    Cascinu S; Fedeli A; Del Ferro E; Luzi Fedeli S; Catalano G
    J Clin Oncol; 1994 May; 12(5):1058-62. PubMed ID: 8164030
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Investigation for the presence of anti-erythropoietin antibodies in patients with myelodysplastic syndromes.
    Voulgari PV; Hatzimichael EC; Tsiara S; Tzallas C; Drosos AA; Bourantas KL
    Eur J Haematol; 2001 Jan; 66(1):31-6. PubMed ID: 11168505
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Phase II clinical study of recombinant human erythropoietin on the anemia associated with multiple myeloma].
    Urabe A; Mizoguchi H; Takaku F; Miyazaki T; Yachi A; Niitsu Y; Miura Y; Mutoh Y; Fujioka S; Nomura T
    Rinsho Ketsueki; 1993 Aug; 34(8):919-27. PubMed ID: 8411646
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effects of recombinant human erythropoietin on autologous blood donation in rheumatoid arthritis patients with anaemia.
    Matsui H; Shiraishi N; Yasuda T; Nezuka T
    Clin Exp Rheumatol; 1999; 17(1):69-74. PubMed ID: 10084035
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Subcutaneous erythropoietin for treatment of refractory anemia in hematologic disorders. Results of a phase I/II clinical trial.
    Cazzola M; Ponchio L; Beguin Y; Rosti V; Bergamaschi G; Liberato NL; Fregoni V; Nalli G; Barosi G; Ascari E
    Blood; 1992 Jan; 79(1):29-37. PubMed ID: 1728318
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prevention of anemia in patients with solid tumors receiving platinum-based chemotherapy by recombinant human Erythropoietin (rHuEpo): a prospective, open label, randomized trial by the Hellenic Cooperative Oncology Group.
    Bamias A; Aravantinos G; Kalofonos C; Timotheadou N; Siafaka V; Vlahou I; Janinis D; Pectasides D; Pavlidis N; Fountzilas G;
    Oncology; 2003; 64(2):102-10. PubMed ID: 12566906
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adding growth factors or interleukin-3 to erythropoietin has limited effects on anemia of transfusion-dependent patients with myelodysplastic syndromes unresponsive to erythropoietin alone.
    Musto P; Sanpaolo G; D'Arena G; Scalzulli PR; Matera R; Falcone A; Bodenizza C; Perla G; Carotenuto M
    Haematologica; 2001 Jan; 86(1):44-51. PubMed ID: 11146570
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical benefits of epoetin alfa (Eprex) 10,000 units subcutaneously thrice weekly in Thai cancer patients with anemia receiving chemotherapy.
    Voravud N; Sriuranpong V
    J Med Assoc Thai; 2005 May; 88(5):607-12. PubMed ID: 16149676
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An extended maintenance dosing regimen of epoetin alfa 80,000 U every 3 weeks in anemic patients with cancer receiving chemotherapy.
    Montoya VP; Xie J; Williams D; Woodman RC; Wilhelm FE
    Support Care Cancer; 2007 Dec; 15(12):1385-92. PubMed ID: 17541653
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recombinant human erythropoietin therapy is very effective after an autologous peripheral blood stem cell transplant when started soon after engraftment.
    Baron F; Frère P; Fillet G; Beguin Y
    Clin Cancer Res; 2003 Nov; 9(15):5566-72. PubMed ID: 14654537
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.